Celecoxib 化学構造
分子量: 381.37

高品質保証

カスタマーフィードバック(2)

MSDS

製品説明

  • Compare COX Inhibitors
    COX製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 セレコキシブは、40nMのIC50による選択的なCOX-2阻害剤です。
ターゲット COX-2
IC50 40 nM [1]
In vitro試験 Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
A549 MUXGeY5kfGmxbjDBd5NigQ>? NVzJOZN[OC5zLUOwJO69VQ>? NH:5[FI1QCCq MUTpcoR2[2W|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=> NGj5OGMzPjVzM{G3Ni=>
H460 NYP4VWNnTnWwY4Tpc44hSXO|YYm= MofrNE4yNTNyIN88US=> NXLhNYpTPDhiaB?= MVTpcoR2[2W|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=> NYPxeWtTOjZ3MUOxO|I>
HKESC-2 NUTPXJZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HJPFIxyqEQvF2= Mm[1OFjDqGkEoB?= MmLGd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJGlEPTEEoI\hcJVmeyCxZjDvfIFtcXCuYYTpcuKh NGrvU4gzPjR5NE[5Ny=>
CaES-17 NWLFSFVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4e2[FIxyqEQvF2= MXO0POKhcMLi NV;wXlJue2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKEmFNUFCpJZidHWnczDv[kBwgGGuaYDsZZRqdsLi MoXCNlY1PzR4OUO=
HKESC-2 M{XSe2Fxd3C2b4Ppd{BCe3OjeR?= M2rDO|IxyqEQvF2= MoXiOFjDqGkEoB?= MlzqdoVlfWOnczDvfIFtcXCuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> MkX2NlY1PzR4OUO=
CaES-17 MmrCRZBweHSxc3nzJGF{e2G7 M4DYflIxyqEQvF2= M{n0NFQ5yqCqwrC= Ml3sdoVlfWOnczDvfIFtcXCuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> MVKyOlQ4PDZ7Mx?=
A549 M1LSOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfVW4U{PS1zNkCg{txO MVS0POKhcMLi MYfEUXNQ NGrC[oVKSzVyPUG2N{41KM7:TR?= NVi1SGhwOjZ2NkS2OFM>
HCC827 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{f2blUuOTZyIN88US=> NX75cG4yPDkEoHlCpC=> NWHoWG1pTE2VTx?= M1[0WWlEPTB;NkmuNkDPxE1? NXjXUGE2OjZ2NkS2OFM>
A549 MoTmRZBweHSxc3nzJGF{e2G7 NXPCbm5SQDBiwsXN M4nRZ|Q5yqCqwrC= MnTSSG1UVw>? MWjpcoR2[2W|IHHwc5B1d3Orcx?= MlixNlY1PjR4NEO=
HCC827 NVfZOolJSXCxcITvd4l{KEG|c3H5 NUX5eopEQDBiwsXN MnHBOFjDqGkEoB?= MUTEUXNQ NUfkUm5KcW6mdXPld{BieG:ydH;zbZM> MX6yOlQ3PDZ2Mx?=
SGC-7901/DDP NEP0TolHfW6ldHnvckBCe3OjeR?= MnTwNVDDqML3TR?= NXn0PY1GOjRiaB?= NIDrZZBqdmirYnn0d{BkgWOub3;4fYdmdmG|ZT2yJIFv\CCSLXfsfYNweHKxdHXpckBmgHC{ZYPzbY9v M2riSFI3PDB5NkWz
SGC-7901  NIr0ZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3ubWEzPMLiaNMg M{PC[GlEPTB;MUG1MlA5KM7:TR?= MYiyOlQxPzZ3Mx?=
SGC-7901/DDP MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWKyOOKhcMLi MlLITWM2OD1|NT60OUDPxE1? M{C2NFI3PDB5NkWz
SGC-7901/DDP MXrBdI9xfG:|aYOgRZN{[Xl? M2PhXVExyqEEtV2= NWHYeGJnOjRiaB?= M{\meYlv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhid3n0bEBkcXOybHH0bY4> MVeyOlQxPzZ3Mx?=
SGC-7901/DDP MnX0SpVv[3Srb36gRZN{[Xl? NUDOc29wOTEEoNM1US=> NYTJeYxsOjRiaB?= M1fCVIlvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJHAu\2y7Y3;wdo91\WmwIITodo92\2hiYnzvZ4tqdmdiRWCyMEBidmRiaX7hZ5RqfmG2aX7nJHBMSSCjbnSgR3JGSsLi M1PXdFI3PDB5NkWz
SGC-7901/DDP MmP1SpVv[3Srb36gRZN{[Xl? NX24SlNCOTEEoNM1US=> MkO4NlQhcA>? NFLqSIJk[XW|ZYOgZUBu[XKtZXSg[IVkemWjc3WgbY4hfGinIHzleoVtKG:oIFLjcE0zKHC{b4TlbY4> NYS5eZZJOjZ2MEe2OVM>
H357 NVPSTZV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17x[lcvPS9zMDFOwG0> M1TB[VQ5KGh? NWXiZmc5TE2VTx?= NYjzenFJcW6qaXLpeJMh[2WubDDndo94fGkEoHPvcYJqdmWmIIfpeIghW2GkdYTvZ4xigA>? Mk\kNlYxODl6N{S=
TAF NGO4c|ZHfW6ldHnvckBCe3OjeR?= MXOxNOKhyrWP Mnu1O{Bl MmjFZYZn\WO2czDURWZ{KGGmaHXzbZZmKHC{b4DldpRq\XN? NVvVenBzOjV7OEexNlc>
TAF M{HIWmZ2dmO2aX;uJGF{e2G7 M1jzXFExyqEEtV2= MVGzNE0yOjBibXnu NVnXPXV2eG:xcnz5JIFn\mWldIOg[GFsfCCyaH;zdIhwenmuYYTpc44h[2:wc3XxeYVvfCC2bzDFS2Yhe2mpbnHsbY5o MUSyOVk5PzF{Nx?=
TAF NYO3clRLTnWwY4Tpc44hSXO|YYm= MnriNVDDqML3TR?= Ml[wOFghcA>? MnHPbY5kemWjc3XzJGVITlJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w MmLtNlU6QDdzMke=
PANC-1 NF\qS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUWyNE83OC9zMECg{txO NIPZZWIzPC92OD:3NkBp NXe5Xnc2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NYr4UoNIOjV7N{OwOlI>
PANC-1 MmDISpVv[3Srb36gRZN{[Xl? NWDUcJhlOjBxNkCvNVAxKM7:TR?= MkLXNlQhcA>? MnXoZZR1\W63YYTzJINmdGxiaX72ZZNqd25iYX7kJI1q\3KjdHnvckBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh M2nH[FI2QTd|ME[y
HeLa  NX3YXGU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXGyNOKh|ryPwrC= MX2yOOKhcA>? NXHjVlNY\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36= NE\0[XczPTd5MESyNy=>
SACC-83 NYTOO2VVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1P3WFIxyqEQvF5CpC=> NUW2UnlHOjUEoHi= Mmn3[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25? M1Tuc|I2PzdyNEKz
HeLa  NUfvSIZVSXCxcITvd4l{KEG|c3H5 M2j0O|IxyqEQvF5CpC=> NYDUPIdVOjUEoHi= NW\YV5Iy\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKGGyb4D0c5Nqew>? MX[yOVc4ODR{Mx?=
SACC-83 NHWweWlCeG:ydH;zbZMhSXO|YYm= NUn1PIJpOjEEoN88UeKh NHLVS40zPMLiaB?= M3jlPIVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBieG:ydH;zbZM> NXTNepdkOjV5N{C0NlM>
HeLa  MoTFSpVv[3Srb36gRZN{[Xl? MUmyNE81OC96MDFOwG0> NVvUZXFDOjUEoHi= NV60PWx4fXC{ZXf1cIF1eyCSVFXOJJBienSrYXzsfUBjgSCrbnjpZol1cW6pIGPwNUwh[W6mIHHjeIl3[XSnczDQWGVPKGGwZDDpcoFkfGm4YYTld{BCU1R? NEPzOIkzPTd5MESyNy=>
SACC-83 NYLMcVBUTnWwY4Tpc44hSXO|YYm= M4DR[|IxNzRyL{iwJO69VQ>? M1X2[FI1yqCq NX3ObW95fXC{ZXf1cIF1eyCSVFXOJJBienSrYXzsfUBjgSCrbnjpZol1cW6pIGPwNUwh[W6mIHHjeIl3[XSnczDQWGVPKGGwZDDpcoFkfGm4YYTld{BCU1R? MlfiNlU4PzB2MkO=
HLCZ01 M1HQW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX2w5qCUPjEEoNM1US=> MXq0PEBp NYHuXINuTE2VTx?= M1TkbYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz Mlz6NlU4OjR6OUm=
HLCZ01 MYfGeY5kfGmxbjDBd5NigQ>? NIO3WnM1OMLizszN NGT6elczPCCq NWPSRVFUTE2VTx?= M4PaN4lv[3KnYYPld{Bi[2O3bYXsZZRqd25ib3[gS|AwTzFvcHjhd4Uh[2WubIOgZ49u[mmwZXSge4l1cCCLRl6t{tE> MmnyNlU4OjR6OUm=
HLCZ01 M1TPXmFxd3C2b4Ppd{BCe3OjeR?= NXSzUWl7PDEEoN88US=> NYjhWWhXOjRiaB?= M1jO[mROW09? M{PydoVvcGGwY3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFnGUk3PuQ>? NEe5Wo8zPTd{NEi5PS=>
HLCZ01 MYrGeY5kfGmxbjDBd5NigQ>? MVO0NOKh|ryP MUSyOEBp NYTFOXU1TE2VTx?= M{D5eYlv[3KnYYPld{BVWkGLTDDlfJBz\XO|aX;uJINwdWKrbnXkJJdqfGhiSX70[ZJn\XKxbj5OtS=> NFjVPJkzPTd{NEi5PS=>
MGC803 NEXm[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYCwMVYxKM7:TR?= M1;TclczKGh? MVnJR|UxRTR5LkK15qCKyrIkgJm2MlQ{KM7:TR?= M2DVT|I2PzBzM{e4
SGC7901 NWH5[Xl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2S2W|AuPjBizszN MlzmO|IhcA>? NYX2eGJZUUN3ME20N{42O+LCidMx5qCKPS5zMjFOwG0> MmDCNlU4ODF|N{i=
MGC803 NXTa[nBbTnWwY4Tpc44hSXO|YYm= NHztWJY1OMLizszN NEixbnU5NzF4L{K0JIg> NX;CSIl1fXC{ZXf1cIF1eyCFYnytZkBmgHC{ZYPzbY9v MV2yOVcxOTN5OB?=
SGC7901 NUfYe5BxTnWwY4Tpc44hSXO|YYm= MVW0NOKh|ryP NVHI[no2QC9zNj:yOEBp M2HC[ZVxemWpdXzheJMhS2KuLXKg[ZhxemW|c3nvci=> MlPBNlU4ODF|N{i=
MCF-7  MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYSxM|ExKM7:TR?= MYO3NkBp MUTEUXNQ NITidoZmdmijbnPld{Bk[WylaYTybY9tNWmwZIXj[YQh[2WubDDndo94fGhiaX7obYJqfGmxbh?= NWf3TFF3OjV4Nke1NVA>
MDA-MB-231  M3LhfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[4PZYyNzFyIN88US=> MWq3NkBp NF;Re5NFVVOR M2DWbIVvcGGwY3XzJINidGOrdILpc4wucW6mdXPl[EBk\WyuIHfyc5d1cCCrbnjpZol1cW:w MW[yOVY3PzVzMB?=
MDA-MB-231 NFrvN2xHfW6ldHnvckBCe3OjeR?= MXGwMVQxKML3TR?= MU[0MVI1KGh? NGnQUVZqdmO{ZXHz[ZMhS0:[LUKgdJJwfGWrbjDlfJBz\XO|aX;uJIlvKGKxdHigeIlu\SCjbnSg[I9{\SCmZYDlcoRmdnRibXHucoVz Ml;KNlU2QDd|Mkm=
MCF-7 NF\Sd5pHfW6ldHnvckBCe3OjeR?= NWT4TGM2OC12MDFCuW0> NEP4ZWM1NTJ2IHi= M3riO4VvcGGwY3XzJJRp\SCnZn\lZ5R{KG:oIGTQRUBwdiCDQlPHNkBmgHC{ZYPzbY9vyqB? M2DMRVI2PTh5M{K5
MCF7-MX  MV3GeY5kfGmxbjDBd5NigQ>? MlfVNE01OCEEtV2= MmfhOE0zPCCq MULlcohidmOnczD0bIUh\W[oZXP0d{Bw\iCWUFGgc44hSUKFR{Kg[ZhxemW|c3nvcuKh M4PRd|I2PTh5M{K5
MDA-MB-231 MXnGeY5kfGmxbjDBd5NigQ>? MYGwMVQxKML3TR?= MUG0MVI1KGh? MmLvd5RqdXWuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBCSkOJMjD1dEB1dyB2LkK3JJRqdWW|IITvJINwdnS{b3ygcIV3\WxiYomgNVIhcMLi MoizNlU2QDd|Mkm=
A2780 NWrHT2NOTnWwY4Tpc44hSXO|YYm= MVe1M|ExNzF3IN88US=> MlywOFghcA>? MkTl[IVkemWjc3XzJGNwgC1{IHX4dJJme3Orb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M2LFTFI2PDJ2OEm4
SKOV3  MU\GeY5kfGmxbjDBd5NigQ>? NFHjXnQ2NzFyL{G1JO69VQ>? MX60PEBp Mn3P[IVkemWjc3XzJGNwgC1{IHX4dJJme3Orb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M1zE[FI2PDJ2OEm4
A2780 MW\GeY5kfGmxbjDBd5NigQ>? M2Tm[|UwOTBxMUWg{txO NX;MTlR2PDhiaB?= MWjlcIV3[XSnczD0bIUh\XiycnXzd4lwdiCxZjDFMYNi\GincnnuJIFv\CCtZYLheIlv MlH4NlU1OjR6OUi=
SKOV3  NH\5fINHfW6ldHnvckBCe3OjeR?= NVvqSnVHPS9zMD:xOUDPxE1? M2HQNVQ5KGh? NWPWeXZO\WyndnH0[ZMhfGinIHX4dJJme3Orb36gc4YhTS2lYXTo[ZJqdiCjbnSgb4Vz[XSrbh?= NVW2fFN5OjV2MkS4PVg>
A2780 MWPGeY5kfGmxbjDBd5NigQ>? MUe1M|ExNzF3IN88US=> MWe0PEBp M1naN4Rm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBPNWOjZHjldolvKGGwZDDWbY1mdnSrbh?= M2H6fVI2PDJ2OEm4
SKOV3  NYXoXJNOTnWwY4Tpc44hSXO|YYm= M1P5OFUwOTBxMUWg{txO MnW5OFghcA>? Mn\j[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJG4u[2GmaHXybY4h[W6mIG\pcYVvfGmw M3HhZ|I2PDJ2OEm4
A2780 MoHkSpVv[3Srb36gRZN{[Xl? MkXnOU8yOC9zNTFOwG0> MYOxJIg> M2DIXIlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBxNUGNVDDhcoQheC2HUlugbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MmKyNlU1OjR6OUi=
SKOV3  NE\XWWpHfW6ldHnvckBCe3OjeR?= MlXhOU8yOC9zNTFOwG0> Moq5NUBp NEjLR41qdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YheC2DS2SgZY5lKHBvRWLLJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NYr2bHhjOjV2MkS4PVg>
HCT-15 NWjmOZdnTnWwY4Tpc44hSXO|YYm= M33KNlExNTVyIN88US=> M{LDNFYuOzZiaB?= M1yzdIlv\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gR29ZNTJiaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MYeyOVIyQDB{OB?=
HT-29  NG\MbpNHfW6ldHnvckBCe3OjeR?= Ml32NVAuPTBizszN MnrVOk0{PiCq NFjCUVlqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNQYC1{IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy NVPq[mV5OjV{MUiwNlg>
HSC3  MUPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHz0VXEx6oDVNECg{txO Mnu1OFghcA>? MmTuTWM2OD1{NT61xtEyNjd6MDFOwG0> MV6yOVE6QDd6OR?=
HSC3  NHezc|hCeG:ydH;zbZMhSXO|YYm= NYH6Vlh6OjVizszN Mkn6OFghcA>? MkftbY5lfWOnczDhdI9xfG:|aYO= NVPk[XFuOjVzOUi3PFk>
HSC3  M4i2Z2Z2dmO2aX;uJGF{e2G7 Mmm3NlUh|ryP M1HWb|Q5KGh? NUHxNFNk\XiqaXLpeJMhe2mpbnnmbYNidnSueTDy[YR2[2WmIH3p[5JifGmxbjDjc41jcW6nZDD3bZRpKEOHVB?= MonCNlUyQTh5OEm=
HSC3  MVHGeY5kfGmxbjDBd5NigQ>? Mn3UNlUh|ryP NWnwXIdjPDhiaB?= NXvjOFZtcW6qaXLpeJMhUFOFMzDj[YxtKGmwdnHzbY9vKGOxbXLpcoVlKHerdHigR2VV NWDlZ|MzOjVzOUi3PFk>
HSC3  M2CzTWZ2dmO2aX;uJGF{e2G7 M4nWfFI2KM7:TR?= NI\ve5Y4OiCq MXfk[YNz\WG|ZYOgUW1RNTJiYX7kJG1OWC17IIDyc5RmcW6|wrC= MVKyOVE6QDd6OR?=
201T  MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPxfmt6PzJiaB?= MVrEUXNQ MX3JR|UxRTR6Lk[gxtVO Mn\rNlUxPTd7NEG=
273T NFjPT4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkiwO|IhcA>? MnXhSG1UVw>? MUjJR|UxRThyLkWgxtVO M1X5NlI2ODV5OUSx
Hep-2 M33QSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUOzNE82OC9zMECg{txO NYrzbVRuOTJxMkSvN|YwPDhiaB?= NVvhc5RXTE2VTx?= M1rN[4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MUOyOFk6QDV4NB?=
Hep-2 NGC2WnhCeG:ydH;zbZMhSXO|YYm= MVi1NEDPxE1? NYiyPZFlOC12ODDo MY\EUXNQ NFT0NIVqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> MlfFNlQ6QTh3NkS=
Hep-2 M2eySGZ2dmO2aX;uJGF{e2G7 NFr6PW02OCEQvF2= M2HS[lAuPDhiaB?= M2LHW2ROW09? MlvSdoVlfWOnczD0bIUhfGWub33ldoF{\SCjY4Tpeol1gSCpcnHkeYFtdHl? MYSyOFk6QDV4NB?=
Hep-2 NGWwdHRHfW6ldHnvckBCe3OjeR?= MV[1NEDPxE1? MmPVNE01QCCq NVf5eHc2TE2VTx?= NWjae3pp\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gbHRGWlR? NYDRXm0xOjR7OUi1OlQ>
SGC-7901 Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXnNVAwPTBxMUCwJO69VQ>? MnrqNlQwPDhxN{KgbC=> M3fJNWROW09? MYrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M2\yVVI1QTl{OUW4
MKN-45 NH;sWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVWxNE82OC9zMECg{txO NH;BfIgzPC92OD:3NkBp MYnEUXNQ MUTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M3XUOVI1QTl{OUW4
SGC-7901 Mn25SpVv[3Srb36gRZN{[Xl? M1nWflExNzVyL{GwNEDPxE1? NFuxPHY1QCCq MVnEUXNQ M3TIWYRwf26{ZXf1cIF1\XNidHjlJI1TVkFiZYjwdoV{e2mxbjDs[ZZmdHNib3[gR29ZNTJiYX7kJHBEVkFiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NIPUbmEzPDl7Mkm1PC=>
MKN-45 NITW[G9HfW6ldHnvckBCe3OjeR?= M3yzU|ExNzVyL{GwNEDPxE1? NFXYSZg1QCCq MnT1SG1UVw>? MWHkc5dvemWpdXzheIV{KHSqZTDtVm5CKGW6cILld5Nqd25ibHX2[Yx{KG:oIFPPXE0zKGGwZDDQR25CKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NGDhT5ozPDl7Mkm1PC=>
C666-1 M{XCeWN6fG:2b4jpZ4l1gSCDc4PhfS=> NUPEcGdROjBvOECg{txO M1HNOlI1KGh? MX7k[YNz\WG|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg MnTvNlQ5PTR6M{i=
CNE-1 M4LDeGN6fG:2b4jpZ4l1gSCDc4PhfS=> NFK2[pYzOC16MDFOwG0> Mo\YNlQhcA>? MYjk[YNz\WG|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg M1fKd|I1QDV2OEO4
CNE-2 M1HjeWN6fG:2b4jpZ4l1gSCDc4PhfS=> NWjYb3lzOjBvOECg{txO MlzMNlQhcA>? NFjOSHJl\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh MmPKNlQ5PTR6M{i=
C666-1 NVrFeGNqS3m2b4TvfIlkcXS7IFHzd4F6 MYe2NEDPxE1? Mor2O{Bl NU[zbI9{\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI> NXq1e|RCOjR6NUS4N|g>
CNE-1 NEjW[ZNEgXSxdH;4bYNqfHliQYPzZZk> NFrrd5I3OCEQvF2= NGLteoU4KGR? M1nES4VvcGGwY3XzJJJi\GmjdHnvckBkgXSxdH;4bYNqfHlidHjyc5VocCCFT2itNk1l\XCnbnTlcpQhdWGwbnXy NW\kRpplOjR6NUS4N|g>
SNU-1041 NF7YcJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnNN4kxNTRyIN88US=> NIDTWXM1QCCq M1LXbIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M134bVI1Pjl{N{Cz
SNU-1041 MnvWSpVv[3Srb36gRZN{[Xl? MmLSNlAwOzBizszN NWn1XnFwPCCq M2LLXYlv\HWlZYOg[ZhxemW|c3nvckBw\sLiQ1jPVEwhT1KSN{lCpIFv\MLiWFLQNeKh[XRidHjlJHJPSSCuZY\lcOKh NVXKNpdXOjR4OUK3NFM>
SNU-1041 NHfuZZNHfW6ldHnvckBCe3OjeR?= Mn34NE01OCEQvF2= MWi0JIg> NET6RZJ2eC2{ZXf1cIF1\XNiQ1jPVOKh[W[2ZYKgeJJm[XSvZX70JJdqfGhiaHnnbEBkd26lZX70doF1cW:wcx?= M4OyfVI1Pjl{N{Cz
SGC-7901 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTVOVAuOTJ3IN88US=> NGDiU2MzPC92OD:3NkBp MVrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MljiNlQ3PzZ|OUS=
SGC-7901 MXnBdI9xfG:|aYOgRZN{[Xl? M1;aRVExOCEQvF2= M{fyWlczKGh? M{POOolv\HWlZYOgZZBweHSxc3nz NY\wbpR{OjR4N{[zPVQ>
SGC-7901 MVnGeY5kfGmxbjDBd5NigQ>? NEfKeG84PS9zMECvNVI2KM7:TR?= NGrBVnEzPC92OD:3NkBp NH\1eItqdmO{ZXHz[ZMh[2G|cHHz[U05KGGwZDCtPUBuWk6DIHX4dJJme3Orb36gbY4h[m:2aDD0bY1mKGGwZDDkc5NmKG2jbn7ldi=> M3Ti[|I1Pjd4M{m0
LMeC  MU\GeY5kfGmxbjDBd5NigQ>? MVyyNE82OCEQvF2= MUm0PEBp NUToSHRX\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEORWD2yJJBzd3SnaX6= NWrCSWV7OjR4NU[3OFY>
CMeC-1 NYfNb5NXS2WubDDWbYFjcWyrdImgRZN{[Xl? NE\0WWIzOC93MDFOwG0> NVfIU|B6PDhiaB?= MnLxbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NXfEPIRLOjR4NU[3OFY>
LMeC Mn7FR4VtdCCYaXHibYxqfHliQYPzZZk> MYWyNE82OCEQvF2= NXjV[2VWPDhiaB?= NF\scYtqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M3XRTFI1PjV4N{S2
CMeC-1 MUjGeY5kfGmxbjDBd5NigQ>? M3rrTVIxNzVyIN88US=> NHXUNoo1QCCq M3HpTolv\HWlZYOgS|EuWyCjcoLld5Q> NXPVSmJPOjR4NU[3OFY>
LMeC MkDoSpVv[3Srb36gRZN{[Xl? NWjLelY2OjBxNUCg{txO MYO0PEBp NUXD[mh5cW6mdXPld{BIOS2VIHHydoV{fA>? MlKyNlQ3PTZ5NE[=
CMeC-1 NIHsc5BHfW6ldHnvckBCe3OjeR?= MnTnNlAwPTBizszN NWPPbFc5PDhiaB?= Monn[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZiY4njcIlvKERzIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NUHESHprOjR4NU[3OFY>
LMeC NWDocVhqTnWwY4Tpc44hSXO|YYm= MoGzNlAwPTBizszN NXLp[lB4PDhiaB?= Mk[2[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZiY4njcIlvKERzIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M37vTVI1PjV4N{S2
CMeC-1 NV\leolrTnWwY4Tpc44hSXO|YYm= M3zwVlIxNzVyIN88US=> NEDBfm41QCCq NX;1bZoxcW6mdXPld{Bk[XOyYYPlMVMh[WO2aY\heIlwdg>? M2\tO|I1PjV4N{S2
LMeC M2rCNGZ2dmO2aX;uJGF{e2G7 MYSyNE82OCEQvF2= MWe0PEBp M3nCZYlv\HWlZYOgZ4F{eGG|ZT2zJIFkfGm4YYTpc44> NHmwfWEzPDZ3Nke0Oi=>
OVCAR-3 MWrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MXixNEDDvU1? MkDUNUBp MULlcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgc5ZiemmjbjDjZY5k\XJiY3XscEBl\WG2aNMg MXqyOFUzODJ{Nx?=
OVCAR-3 MYPBdI9xfG:|aYOgRZN{[Xl? NVrIfXp[OTBiwsXN MVqxJIg> NYXLRWtueHKxbX;0[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGGyb4D0c5Nqe8Li NV;hfppPOjR3MkCyNlc>
OVCAR-3 Mk[3SpVv[3Srb36gRZN{[Xl? MUCxNEDDvU1? M1W5TFEhcA>? NX3aWHZQ\W6qYX7j[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGGldHn2ZZRqd25ib3[gZ4F{eGG|ZT25xsA> MXOyOFUzODJ{Nx?=
OVCAR-3 NHrh[o5HfW6ldHnvckBCe3OjeR?= MX[xNEDDvU1? MoHINUBp MYDkc5dvNXKnZ4XsZZRmeyCQRj5OvmIh[WO2aY\heIlwdiCrbnT1Z4VlKGK7IIDhZ4xqfGG6ZXy= M1HxO|I1PTJyMkK3
OVCAR-3 MWTGeY5kfGmxbjDBd5NigQ>? M2qyOFExKML3TR?= NHqyPFgyKGh? MVTpcohq[mm2czDwZYNtcXSjeHXsMYlv\HWlZXSgRYt1KHCqb4PwbI9zgWyjdHnvci=> NWTD[5NoOjR3MkCyNlc>
CF33 M1\2UmZ2dmO2aX;uJGF{e2G7 Mnv3NVAxKM7:TR?= MXOyOEBp NGnyPXBqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbh?= NUe1[WVqOjR3MEO3PFI>
CF33 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mor6NVAuOTByIN88US=> NWXuXW1SOC12IHS= MoP0bY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NUTuU2JMOjR3MEO3PFI>
CF33 Mn;hSpVv[3Srb36gRZN{[Xl? MXSxNE0yODBizszN NFfzUFc1NTJ2IHi= MUjk[YNz\WG|ZYOgZ4VtdHNiaX6geIhmKFNicHjhd4Uh[W6mIHnuZ5Jm[XOnczDj[YxteyCrbjDHNE9IOSCjcoLld5Q> MUCyOFUxOzd6Mh?=
LNCaP M4HPOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX2bW1{Oi93L{GwJO69VQ>? NGLqSFY6PiCq MnPPbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKGG2b4L2ZZN1[XSrbh?= MUeyOFI6Pjl5OB?=
LNCaP MUXBdI9xfG:|aYOgRZN{[Xl? M1zEZ|IwPS9zMDFOwG0> MnW0PVYhcA>? NEPDeoRqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> NXL1[nFLOjR{OU[5O|g>
PC-3  NYjYXnRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnS1NE02OCEQvF2= MXm0PQKBkWh? MYrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NXHmZ3JiOjRzMke4PFI>
PC-3  M3nqPWNmdGxiVnnhZoltcXS7IFHzd4F6 Mn;MNE0yODBizszN NYHwSohGPzJiaB?= NITCfG5l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NVzvd5pTOjRzMke4PFI>

... Click to View More Cell Line Experimental Data

In vivo試験 Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]
臨床試験 Celecoxib is currently in Phase II clinical trials in patients with recurrent respiratory papillomatosis.
特集

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

COX enzyme assay in vitro Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.

細胞アッセイ: [2]

細胞株 HNE1 and CNE1-LMP1
濃度 0-75 μM
反応時間 48 hours
実験の流れ The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.

動物実験: [1]

動物モデル A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
製剤 Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
投薬量 ≤200 mg/kg
投与方法 Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Celecoxib SDF
分子量 381.37
化学式

C17H14F3N3O2S

CAS No. 169590-42-5
保管 3年-20℃
2年-80℃in solvent
別名 SC 58635
溶解度 (25°C) * In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water <1 mg/mL
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 4-(5-p-tolyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide

文献中の引用 (6)

Frequently Asked Questions

  • Question 1
    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

    Answer: For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related COX 阻害剤

  • Xanthohumol

    Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. Phase 1.

  • AZD3839

    AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.

  • A-438079 HCl

    A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.

  • PF-03084014 (PF-3084014)

    PF-03084014 (PF-3084014) is a selective gamma-secretase inhibitor with IC50 of 6.2 nM in a cell-free assay. Phase 2.

  • Indomethacin

    Indomethacin(Indocid, Indocin) is a non-steroidal anti-inflammatory compound commonly used to reduce fever, pain, stiffness, and swelling.

  • Lornoxicam

    Lornoxicam is a COX-1 and COX-2 inhibitor with IC50 of 5 nM and 8 nM, respectively.

  • Aspirin

    Aspirin is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication.

  • Rofecoxib

    Rofecoxib is a COX-2 inhibitor with IC50 of 18 nM.

  • Ketorolac

    Ketorolacは非選択COX阻害剤、人間COX-1とCOX-2に作用する時、IC50がそれぞれ1.23 µM と3.50 µM になる。

    Features:A COX-1 preferential inhibitor among currently marked nonsteroidal anti-inflammatory drugs (NSAIDs).

最近チェックしたアイテム

Tags: Celecoxibを買う | Celecoxib供給者 | Celecoxibを購入する | Celecoxib費用 | Celecoxib生産者 | オーダーCelecoxib | Celecoxib代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ